Phase I Multiple-Ascending Dose (Japan)

NCT00538174 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Dapagliflozin
DRUG: placebo

Sponsor

AstraZeneca